TITLE

A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer

AUTHOR(S)
Ikuo Sekine; Hiroaki Okamoto; Takeshi Horai; Kazuhiko Nakagawa; Hironobu Ohmatsu; Akira Yokoyama; Nobuyuki Katakami; Masahiko Shibuya; Nagahiro Saijo; Masahiro Fukuoka
PUB. DATE
March 2014
SOURCE
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p96
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94754942

 

Related Articles

  • Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. Reck, Martin; von Pawel, Joachim; Macha, Hans-Nicolas; Kaukel, Eckhard; Deppermann, Karl-Matthias; Bonnet, Reiner; Ulm, Kurt; Hessler, Sybill; Gatzemeier, Ulrich // JNCI: Journal of the National Cancer Institute;8/06/2003, Vol. 95 Issue 15, p1118 

    Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etoposide) and carboplatin is an effective and safe first-line treatment for patients with small-cell lung cancer (SCLC). We conducted a randomized phase III multicenter trial to determine...

  • Pharmion's Amrubicin Begins Pivotal Trial In SCLC Patients. Boggs, Jennifer // BioWorld Today;10/18/2007, Vol. 18 Issue 203, p1 

    The article reports on the pivotal trial of amrubicin, a third-generation anthracycline, in patients with small cell lung cancer (SCLC) by Pharmion Corp. According to Andrew Allen, executive vice president and chief medical officer of Pharmion, the Phase III study will use a conventional...

  • A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Inoue, A.; Ishimoto, O.; Fukumoto, S.; Usui, K.; Suzuki, T.; Yokouchi, H.; Maemondo, M.; Kanbe, M.; Ogura, S.; Harada, T.; Oizumi, S.; Harada, M.; Sugawara, S.; Fukuhara, T.; Nukiwa, T. // Annals of Oncology;Apr2010, Vol. 21 Issue 4, p800 

    Background: Amrubicin, a new anthracycline agent, has shown high activity for small-cell lung cancer (SCLC) in previous studies. However, a combination regimen with amrubicin and platinum has been investigated little. On the basis of previous phase I study, we conducted this study to evaluate...

  • Randomized Phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. Halmos, Balazs // Current Medical Literature: Lung Cancer;2013, Vol. 7 Issue 2, p49 

    The article discusses research on the treatment of advanced non-small-cell lung cancer. It references the study "Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group...

  • Chemotherapy and Radiotherapy.  // Current Medical Literature: Lung Cancer;2012, Vol. 5 Issue 3, p82 

    The article discusses several studies on chemotherapy and radiotherapy as treatment options for lung cancer. Researchers from Royal Marsden Hospital investigated the use of amrubicin as single-agent or in combination with cisplatin versus cisplatin etoposide as first-line therapy in patients...

  • A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer. Harada, T.; Hamada, A.; Shimokawa, M.; Takayama, K.; Kudoh, S.; Maeno, K.; Saeki, S.; Miyawaki, H.; Moriyama, A.; Nakagawa, K.; Nakanishi, Y. // Japanese Journal of Clinical Oncology;Feb2014, Vol. 44 Issue 2, p127 

    Objective This study reports the findings of a Phase I/II, cohort, dose-escalation trial of amrubicin and irinotecan with the support of granulocyte colony-stimulation factor. This study aimed to determine the dose-limiting toxicity of the combination and to define the maximum-tolerated dose, as...

  • Adverse Reaction Research.  // Reactions Weekly;6/13/2009, Issue 1256, p5 

    The article discusses research on the association between interstitial lung disease (ILD) and the use of amrubicin in the treatment of patients with small cell lung cancer (SCLC). It references a study by K. Yoh et al presented at the 45th Annual Meeting of the American Society of Clinical...

  • Lung Cancer.  // Current Medical Literature: Respiratory Medicine;2009, Vol. 23 Issue 3, p74 

    The article summarizes studies related to lung cancer. The study "Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial," by R. Pirker et al assessed patients with stage IIIB or stage IV non-small-cell lung cancer. It...

  • Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. Hatfield, Laura A.; Huskamp, Haiden A.; Lamont, Elizabeth B. // Journal of Oncology Practice;Jul2016, Vol. 12 Issue 7, p665 

    Purpose Elderly patients with cancer are under-represented in clinical trials and risk greater toxicity from chemotherapy. These patients and their physicians need better evidence to decide among guideline-recommended regimens. We test whether patients with extensive-stage small-cell lung cancer...

  • Lung Cancer in the Elderly: Current and Future Chemotherapeutic Options. Hinton, S.; Sandler, A. // Drugs & Aging;2002, Vol. 19 Issue 5, p365 

    Lung cancer is a prevalent malignancy disproportionately affecting the elderly, and in our aging societies will only increase in magnitude. Physicians typically assume that elderly lung cancer patients will have poorer prognoses. This belief is in part based on certain physiological changes of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics